Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silo Pharma, Inc. (Nasdaq: SILO) SEC filings page on Stock Titan provides direct access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Silo’s status as a developmental-stage biopharmaceutical and cryptocurrency treasury company, its capital structure, and its governance and compliance framework.
For investors analyzing Silo’s biopharmaceutical programs and digital assets strategy, key filings include current reports on Form 8-K, the Definitive Proxy Statement (DEF 14A), and registration statements such as Form S-1. Recent 8-Ks describe material events including the launch of a cryptocurrency advisory board, asset purchases related to crypto software and domains, Nasdaq minimum bid price notifications, strategic agreements with Fireblocks for digital asset custody, and securities purchase agreements for registered direct offerings and concurrent private placements.
The Form S-1 registration statement filed in October 2025 details the resale of shares issuable upon exercise of investor and placement agent warrants issued in a financing transaction, including warrant terms, exercise prices, and potential proceeds if exercised. This document helps readers understand how warrant exercises could affect Silo’s share count and capital resources.
Silo’s DEF 14A proxy statement outlines matters submitted to shareholders at the 2025 annual meeting, such as director elections, ratification of the independent registered public accounting firm, authorization of a reverse stock split within a specified range, and an amendment to increase shares reserved under the equity incentive plan. An 8-K reporting the voting results shows how shareholders acted on these proposals.
Additional 8-K filings cover topics such as an evaluation license and option agreement with the University of Maryland, Baltimore for intellectual property related to central nervous system-homing peptides and the establishment of a cryptocurrency advisory board with related equity compensation. Together, these documents provide a regulatory record of Silo’s efforts to advance its SPC-15 and SP-26 programs, manage listing compliance on the Nasdaq Capital Market, and implement its crypto treasury strategy.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can be used to quickly surface items related to financings, listing compliance, governance changes, and strategic agreements within Silo Pharma’s disclosure history.
Silo Pharma, Inc. Chief Executive Officer and director Eric Weisblum reported purchases of the company’s common stock. On December 15, 2025, he bought 2,500 shares at $0.41 per share and another 2,500 shares at $0.42 per share. After these transactions, he directly beneficially owned 216,932 shares of Silo Pharma common stock.
Silo Pharma, Inc. (SILO) CEO and director Eric Weisblum reported open-market purchases of company stock. On 11/20/2025, he bought 1,000 shares of common stock at $0.37 per share. On 11/21/2025, he purchased another 1,000 shares at $0.365 per share. Following these transactions, Weisblum beneficially owns 211,932 shares of Silo Pharma common stock, held directly.
Silo Pharma, Inc. insider share purchases reported
A reporting person serving as both a director and Chief Executive Officer of Silo Pharma, Inc. (SILO) filed a Form 4 disclosing open‑market purchases of the company’s common stock. On November 18, 2025, the insider purchased 7,500 shares at a weighted average price of $0.4033 per share. On November 19, 2025, the insider purchased an additional 4,500 shares at a weighted average price of $0.405 per share. Following these transactions, the insider directly owns 209,932 shares of Silo Pharma common stock.
Silo Pharma, Inc. (SILO) filed its Q3 2025 10‑Q, reporting a net loss of $1,110,438 for the quarter and $3,346,168 for the nine months ended September 30, 2025. License fee revenue was $18,025 in the quarter and $54,076 year‑to‑date, with cost of revenues of $20,687 in the quarter.
Operating expenses were led by R&D at $543,615 in the quarter ($1,854,824 YTD), plus compensation and professional fees. As of September 30, 2025, cash and cash equivalents were $3,917,627, short‑term investments $1,948,579, total assets $6,384,681, and working capital $5,456,030. The company states it has sufficient cash and liquid short‑term investments to meet obligations for a minimum of twelve months from the date of the filing.
During 2025, Silo completed a May public offering with net proceeds of $1,593,897 and received warrant exercise proceeds of $500,000 on June 6 and $634,922 during August–September. It also issued 750,000 shares valued at $518,225 for software assets, recorded as R&D. Crypto assets totaled $72,283 at fair value as of September 30, 2025. Shares outstanding were 13,318,273 as of November 13, 2025.
Silo Pharma, Inc. filed an S-1 registering up to 3,071,428 shares of common stock for resale by selling shareholders. These shares are issuable upon exercise of warrants issued in an October 1, 2025 financing: 2,857,143 Investor Warrant shares at an exercise price of $0.75 per share and 214,285 Placement Agent Warrant shares at $1.0938 per share. The company will not receive proceeds from the resale.
The company may receive cash only if holders exercise the warrants, which would total approximately $2.38 million in aggregate gross proceeds upon full cash exercise. Shares outstanding were 13,318,273 as of October 27, 2025; the filing notes 16,389,701 assuming full warrant exercise. The common stock trades on Nasdaq as SILO; the last reported sale price was $0.5690 on October 27, 2025.
Silo Pharma (SILO) reported results from its October 24, 2025 annual meeting. Shareholders approved giving the Board discretionary authority to effect a reverse stock split of the common stock at a ratio between 1-for-2 and 1-for-20, without reducing the authorized shares, which may be effected at any time before October 24, 2026.
Shareholders also approved an amendment to the 2020 Omnibus Equity Incentive Plan to increase the stock reserve to 1,400,000 shares from 470,000. All four directors—Eric Weisblum, Wayne Linsley, Kevin Muñoz and Jeff Pavell—were re-elected, and Salberg & Company, P.A. was ratified as independent auditor for fiscal 2025. An adjournment proposal was approved as well. A quorum of 5,142,415 shares was represented in person or by proxy.
SILO issuer Silo Pharma, Inc. has a Schedule 13G filed by SEG Opportunity Fund, LLC reporting beneficial ownership of 952,381 shares of common stock, representing 7.1% of the class based on 13,318,273 shares outstanding after a Registered Direct Offering closed October 1, 2025. The filing shows shared voting and shared dispositive power over those shares and no sole voting or dispositive power.
The filer certifies the shares were not acquired to change or influence control of the issuer. The filing is dated 10/03/2025 and lists SEG Opportunity Fund as a New York LLC with its address in Roslyn, NY. This is a passive ownership disclosure under Schedule 13G.
Silo Pharma, Inc. entered into a securities purchase agreement with institutional investors to raise approximately $2.5 million in gross proceeds. The company sold 2,857,143 shares of common stock at $0.875 per share under its effective shelf registration statement.
For each share purchased, investors received an unregistered warrant to buy one additional share of common stock at an exercise price of $0.75 per share. These warrants are exercisable immediately and expire five years after a registration statement covering the warrant shares becomes effective.
Silo engaged H.C. Wainwright & Co. as exclusive placement agent, agreeing to pay cash fees totaling 8.5% of gross proceeds and to issue placement agent warrants for up to 214,285 shares at an exercise price of $1.0938 per share. The company plans to use net proceeds for working capital and general corporate purposes and agreed to short-term restrictions on issuing additional equity and a one-year prohibition on variable rate transactions.
Silo Pharma, Inc. (SILO) published a prospectus supplement describing a securities offering intended to raise net proceeds of approximately $2.15 million after placement agent fees and estimated expenses. The supplement identifies an offering price and placement agent fees that produce gross proceeds shown as $2,312,500.12 before expenses and net proceeds of about $2.15 million to be used for general corporate and working capital purposes. The document lists 2,857,143 shares in connection with Unregistered Warrants and total potential dilution from numerous outstanding options and warrants, including large tranches exercisable at prices ranging from $0.60 to $6.25 per share and specific counts such as 4,773,340 shares issuable upon exercise of May 2025 Warrants at $0.60 and 2,857,143 shares issuable upon exercise of Unregistered Warrants at $0.75. The filing emphasizes high risks, including need for additional financing, no history of profitable operations, regulatory and controlled-substance risks for psilocybin-based candidates, potential dilution, and Nasdaq listing risk.
Silo Pharma, Inc. presents a definitive proxy statement covering board composition, governance matters and executive compensation. The board is nominating four directors including Eric Weisblum (Chairman, CEO, President) and three director nominees: Wayne Linsley, Dr. Kevin Muñoz and Dr. Jeff Pavell. The proxy describes voting standards for director elections and shareholder approvals tied to majority or plurality votes as applicable.
Key compensation disclosures show Daniel Ryweck's employment agreement calling for a $60,000 annual base salary and eligibility for an annual discretionary bonus up to $60,000. The filing reports company contributions to executives' 401(k) plans and payment of health insurance premiums. The proxy discloses equity plan details: an Amended and Restated 2020 Omnibus Equity Incentive Plan expanded to 470,000 shares and current reserved instruments including 8,295,072 shares for warrants and 467,850 shares for options/RSUs. The statement also includes a shareholder-authorized reverse stock split framework to be fixed within an approved ratio by the board.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
